Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8NAX2
UPID:
KDF1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8NAX2; Q5QP32; Q8N0S7
Background:
Keratinocyte differentiation factor 1 plays a pivotal role in epidermis formation during early development. It is essential both as an inhibitor of basal cell proliferation and as a promoter of differentiation for basal progenitor cell progeny. This protein's function underscores its importance in the structural and functional integrity of the skin.
Therapeutic significance:
Ectodermal dysplasia 12, a disorder characterized by sparse hair, abnormal teeth, and an inability to sweat, is linked to variants affecting Keratinocyte differentiation factor 1. Understanding the role of this protein could unveil novel therapeutic strategies for managing this condition.